Navigation Links
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Date:2/6/2009

lness, insomnia and pruritus.

Reoccurrence of thrombocytopenia and bleeding after cessation of treatment and increased bone marrow reticulin have been associated with romiplostim treatment in the clinical trials. Thrombotic/thromboembolic complications, progression of existing haematopoietic malignancies or myelodysplastic syndromes (MDS), and effects on red and white blood cells are all potential risks associated with romiplostim treatment. As with all therapeutic proteins, patients may develop antibodies to the therapeutic protein.

Important U.S. Nplate Safety Information

Serious adverse reactions associated with Nplate in clinical studies were bone marrow reticulin deposition and worsening thrombocytopenia after Nplate discontinuation. Additional risks include bone marrow fibrosis, thrombotic/thromboembolic complications, lack or loss of response to Nplate, and haematological malignancies and progression of malignancy in patients with a pre-existing haematological malignancy or myelodysplastic syndromes (MDS). Nplate is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

In the U.S. Nplate is available only through a restricted distribution program called Nplate(TM) NEXUS (Network of Experts Understanding and Supporting Nplate and Patients) Program.

In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cance
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The Bio-Process Systems Alliance (BPSA) is pleased ... (ISUS 2015) will be held July 13-15, 2015, ... primary focus on the promises and hurdles impacting the ... to business and regulatory presentations, ISUS 2015 will examine ... single-use industry as the "go-to" platform in bioprocessing. The ...
(Date:5/27/2015)... Manitoba , May 27, 2015 ... customers, the Canadian International Pharmacy Association (CIPA) ... medications online from licensed Canadian pharmacies. Approximately 64% of ... maintenance medications from a non-U.S. pharmacy due to ... are not covered under their insurance plan.   ...
(Date:5/27/2015)... ANGELES , May 27, 2015  CytRx Corporation ... company specializing in oncology, today announced an upcoming poster ... 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, ... 2015 in Chicago . ... profile we,re seeing in patients who have undergone treatment ...
Breaking Medicine Technology:BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 2BPSA's 5th Annual Summit to Provide '2020 Vision' for Single-Use Technologies 3Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 2Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 2CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 3CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 4CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting 5
... WIRE)--Jun 27, 2007 - Annals of,Internal Medicine has ... the impact of genistein on bone loss. The ... in Osteopenic,Postmenopausal Women-A Randomized Trial," appears in the ... and efficacy of,genistein for the dietary management of ...
... - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), a company involved ... presented,poster presentations at the 5th International Society ... Cairns, Queensland, Australia,from June 17-20 and at ... for Cellular Therapy (ISCT) in Sydney, Australia ...
Cached Medicine Technology:New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine 2New Proof of Genistein's Efficacy and Safety for Osteopenia and,Osteoporosis Published in Annals of Internal Medicine 3Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3
(Date:5/27/2015)... TX (PRWEB) May 27, 2015 Congratulations ... The Torch” Addiction Treatment Scholarship Award. From June 1, ... $10,000 to 50 drug and alcohol addiction treatment centers ... treatment. Scholarships were drawn at random at addiction treatment ... for Sky Toxicology, Matt Green said, “Sky Toxicology would ...
(Date:5/27/2015)... Danish scientists have published an analysis of ... potential to help in diagnosis or treatment planning for ... that has just been posted on Surviving Mesothelioma. ... new biomarkers found in blood, serum, and lung fluid ... malignant mesothelioma . , Study author Vasiliki Panou ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 With the ... Studios, editors can quickly and easily add filmic color grades ... CUBE LUT files. , FCPX LUT Cross Processed Plugin can ... to contemporary looks and everything in between. , FCPX LUT ... be used in many different softwares. With the FCPX LUT ...
(Date:5/27/2015)... May 27, 2015 Widely regarded ... center for young adults ages 18 to 40, ... accreditation by The Joint Commission. The announcement ... Scottsdale, AZ regions, entailing a number of added ... detox and residential treatment program in lieu of ...
(Date:5/27/2015)... Lutz, Florida (PRWEB) May 27, 2015 ... with its digital partner, award winning web ... is proud to announce the launch of ... http://www.nationalhealthcareproviders.com. , National Healthcare Providers, ... consulting firm, specializing in the areas of ...
Breaking Medicine News(10 mins):Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release FCPX LUT Cross Processed Plugin for Final Cut Pro X 2Health News:Arizona Drug Treatment Center SRC Announces JCAHO Accreditation 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3
... Scientists involved in a worldwide research have come up with ... ,This gel is expected to evolve into a powerful new ... it would be 95% efficient. ,Brazilian scientists, ... by using microbicides , assure the gel will be on ...
... Novacea , a drug company has designed a vitamin D ... D from sunlight is known to slow down certain cancers. ... effect. The drug, Asentar (DN-101) provides levels of vitamin D ... patients in the advanced stages of prostate cancer along with ...
... role of partners or couples in health care, according to ... of Archives of Dermatology, researchers came to the conclusion that ... to take the sessions more seriously and do the examination ... the dreaded melanoma or skin cancer. , Persons ...
... may exist a link between Vitamin A and gullet cancer. ... Research Council Cell Unit and her team. // ,Gullet ... the oesophageal lining. This condition is also called as Barrett’s ... is slowly changed to glandular lining. The reason for this ...
... South Asians have been known to get first-time heart attacks ... but this had been put down loosely to genes.,Not any ... researchers has come out with findings published in Journal of ... Asians (people originating from India, Pakistan, Srilanka, Nepal and. ...
... and health care clinics in China have been asked ... prepared to handle cases. //The Ministry of Health has ... rise in diarrhea cases. ,As Norovirus infections ... while eating in restaurants and hotels. These viruses are ...
Cached Medicine News:Health News:Vitamin D Tablets to Cure Prostate Cancer 2Health News:Pair Up-Prevent Melanoma 2Health News:South Asians, Don’t Blame Your Genes Anymor 2
... First Stop absorbable collagen hemostat. FirstStop is ... handling and removal characteristics. It can easily ... fit the wound. FirstStop products are not ... peeled away after hemostasis is achieved. As ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: